Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SSY Group ( (HK:2005) ) has issued an announcement.
SSY Group Limited announced that its Vitamin A Palmitate has received approval from the National Medical Products Administration of China, allowing it to be marketed as a bulk drug for vitamin supplement injections. This development marks a significant step in the company’s product offerings, potentially enhancing its market position and providing new opportunities for growth in the pharmaceutical sector.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of bulk drugs and vitamin supplements. The company is known for its work in creating fat-soluble vitamin injections, with a particular emphasis on Vitamin A Palmitate.
Average Trading Volume: 14,026,037
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.79B
For an in-depth examination of 2005 stock, go to TipRanks’ Overview page.